Vita Genomics, Inc. was established in 2001 by Ellson Chen, the chief scientist of the Human Genome Project. Vita Genomics is dedicated to human genomics research and provides comprehensive services and solutions to pharmaceutical and biotechnology companies worldwide. The molecular testing laboratory h has been accredited to ISO/IEC 17025 since 2006 and has maintained this accreditation continuously. The laboratory is also certified by the Taiwan Food and Drug Administration (TFDA) as a Precision Medicine Molecular Testing Laboratory.

Vita Genomics focuses on developing innovative and differentiated testing services that address unmet clinical needs. A prime example is the molecular test for Attention-Deficit/Hyperactivity Disorder (ADHD), a globally unprecedented breakthrough in clinical diagnostics. Furthermore, as cancer has remained the leading cause of death in Taiwan for 44 consecutive years, Vita Genomics has built a comprehensive portfolio of cancer testing services spanning the entire cancer care continuum. Our offerings include hereditary cancer risk assessment, multi-cancer early detection (MCED), personalized treatment selection, and post-treatment monitoring.

Vita Genomics’ testing services are designed to support healthcare providers across the entire healthcare system. Our customers include health examination centers, medical centers, hospitals, and clinics.